Compare RRGB & CVRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RRGB | CVRX |
|---|---|---|
| Founded | 1969 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Restaurants | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 133.6M | 139.8M |
| IPO Year | 2002 | 2021 |
| Metric | RRGB | CVRX |
|---|---|---|
| Price | $7.50 | $4.95 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 4 |
| Target Price | $9.00 | ★ $10.50 |
| AVG Volume (30 Days) | 165.7K | ★ 242.8K |
| Earning Date | 05-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.43 | 23.02 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,315,014,000.00 | $56,651,000.00 |
| Revenue This Year | N/A | $17.17 |
| Revenue Next Year | N/A | $17.69 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 10.45 |
| 52 Week Low | $2.46 | $4.37 |
| 52 Week High | $8.26 | $11.30 |
| Indicator | RRGB | CVRX |
|---|---|---|
| Relative Strength Index (RSI) | 66.13 | 44.24 |
| Support Level | $6.26 | $4.59 |
| Resistance Level | $8.26 | $5.96 |
| Average True Range (ATR) | 0.41 | 0.32 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 91.01 | 22.22 |
Red Robin Gourmet Burgers Inc is a restaurant operator. The company develops, operates, and franchises casual-dining restaurants and fast-casual restaurants in North America. The company's brands are Red Robin, Red Robin Gourmet Burgers, Red Robin America's Gourmet Burgers and Spirits, Red Robin Burger Works, YUMMM, Red Robin Gourmet Burgers and Brews, and Red Robin Royalty names and logos. The company's revenue consists of sales from restaurant operations, gift card breakage, franchise royalties and fees, and other miscellaneous revenue. It has one operating and one reportable segment: restaurants.
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.